One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2018-99-111369
Copy DOI Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 3 |
Affiliation: Ospedale Niguarda Ca' Granda, Autonomous University of Barcelona, Hospital de Sant Pau, University of California, San Diego, North Shore Hospital, Queen Mary University of London, Paracelsus Medical University, The University of Texas MD Anderson Cancer Center, Tel Aviv University, Rabin Medical Center, Tennessee Oncology, Sarah Cannon, Princess Alexandra Hospital, Copernicus Memorial Hospital, Medical University of Lodz, Pharmacyclics (United States), AbbVie (United States), Norton Healthcare, Dokuz Eylül University, Janssen (United Kingdom), University of Eastern Piedmont Amadeo Avogadro, University of Rochester Medical CenterSingle-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
